Endocrine Abstracts

Introduction: Gestational diabetes (GD) is a known risk factor for delivery, fetal and perinatal complications. Fetal male sex is known to be associated with worse perinatal outcomes, such as macrosomia, neonatal hypoglycemia, low Apgar scores, birth defects and mortality. However, studies evaluating the impact of fetal sex on perinatal outcomes in women with GD are scarce. Objectives: We aimed to study whether male newborn sex is associated with neonata...

Introduction: Women with gestational diabetes (GD) have an increased risk of developing future type 2 diabetes mellitus (T2DM). A reclassification oral glucose tolerance test (OGTT) is currently recomended in the postpartum period. However, most studies report a compliance rate below 50% and as low as 23%.Objectives: We aimed to study predictors of missing postpartum OGTT in women with GD.Materials and Methods: Retrospecti...

Introduction: There are several known risk factors for gestational diabetes mellitus (GDM), a condition associated with worse pregnancy outcomes. Once GDM is established, the association between the presence of GDM risk factors and pregnancy outcomes is less well-known. We studied the association between the number of GDM risk factors and pregnancy outcomes in a population of women with GDM.Methods: Retrospective study of the Portuguese multicentre GDM r...

Introduction: Hyperglycaemia has been associated with worse maternal and foetal outcomes as well as higher risk for future type 2 diabetes (T2D).Objectives: We study the association between glucose above diagnostic threshold (GADT) at gestational diabetes (GD) diagnosis and risk of perinatal complications and maternal glucose abnormalities at post-partum.Materials and Methods: Retrospective study based on the national register of G...

Introduction: Gestational diabetes (GD) is defined as a glucose intolerance firstly recognized during pregnancy and it is the severity of hyperglycaemia which is relevant to maternal and foetal risks. The American Diabetes Association (ADA) recommends screening before 15 weeks of gestation for women at risk, using standard diagnostic criteria, and defines early abnormal glucose metabolism as fasting glucose 110-125 mg/dl or HbA1c 5.9-6.4%. However, the benefit of treating wome...